Hollie Franklin, Author at Drugs in Context

Primary genetic disorders affecting high density lipoprotein (HDL)

Constantine E Kosmas MD, PhD, Delia Silverio MD, Andreas Sourlas, Frank Garcia MD, Peter D Montan MD, Eliscer Guzman MD

Article Type

Review

Published

18 Sep 2018

This review aims to describe certain genetic disorders associated with either low or high plasma HDL-C and discuss their clinical features, associated risk for cardiovascular events, and treatment options.

Spectral Doppler and automated software-guided ultrasound assessment of bilateral common carotid intima-media thickness in spondyloarthritis: is there a correlation with clinical findings?

José Alexandre Mendonça PhD, Beatriz Bisetto de Andrade MD, José Luis Braga de Aquino PhD, Vania Aparecida Leandro-Merhi PhD, Guilherme B Damian MD

Article Type

Original Research

Published

03 Sep 2018

This study evaluates the correlation between articular and carotid ultrasound data and laboratory and clinical variables in patients with spondyloarthritis.

Role of betamethasone valerate 2.250 mg medicated plaster in the treatment of psoriasis and other dermatological pathologies: a review

Sandra Ly MD, Jean Michel Amici MD

Article Type

Review

Published

20 Aug 2018

This review presents the available clinical data from studies with betamethasone valerate medicated plaster in the treatment of psoriasis and other dermatoses and discusses its place in therapy for dermatological conditions.

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy

Yue Zhao MD, Rishi P Singh MD

Article Type

Review

Published

13 Aug 2018

This review discusses recent clinical trials and guidelines for anti-VEGF use in proliferative diabetic retinopathy.

Advances in the use of PARP inhibitor therapy for breast cancer

Kelly E McCann MD, PhD, Sara A Hurvitz MD

Article Type

Review

Published

08 Aug 2018

In the care of oncology patients, poly-ADP-ribose polymerase (PARP) inhibitors are best known as a semitargeted treatment
for BRCA1- and BRCA2-associated ovarian and breast cancers, this article reviews the broader understanding of PARP biology that has spurred interest in expanding their clinical utility.